Phase 1/2 Trials
DMT Therapy
DMT (dimethyltryptamine) is a powerful psychedelic being studied for depression and end-of-life anxiety. Its short duration of action (15-30 minutes) makes it potentially more practical for clinical settings.
50Clinical Trials
2Companies
1Legal States
FDA StatusPhase 1/2 Trials
Legal PathwayFDA approval pathway (federal)
Also Known Asdimethyltryptamine, N,N-DMT, spirit molecule
Legal Status by State
View full legal tracker →Fully Operational
Legal, Launching
Decriminalized
Active Legislation
Research Only
No Activity
Decriminalized1
CO
Clinical Trials
9 trials currently recruiting
Phase 119
Phase 25
Phase 37
Active, Not Recruiting·Phase 2·DMT
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Cybin IRL Limited
Generalized Anxiety Disorder
Active, Not Recruiting·Phase 1·DMT
Single and Repeat Doses of DMT in Healthy Subjects
Algernon Pharmaceuticals
Stroke
Active, Not Recruiting·Phase 4·DMT
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Active, Not Recruiting·Phase 1·DMT
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
Major Depressive DisorderDepression
Active, Not Recruiting·N/A·DMT
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
Multiple Sclerosis
Active, Not Recruiting·Phase 3·DMT
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Rennes University Hospital
Multiple Sclerosis
Companies & Research
Organizations developing DMT-based therapies